BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Exploring the Difficulties of Beginning a Family: Individual Experiences - 2Artemis 2 astronauts are now headed to the moon. Why has it taken humanity so long to go back?
- 3Ministry: New German petrol price regulation takes effect on April 1
- 4How Deforestation Is Reshaping Mosquito-Human Contact
- 5Google's proposed data center in orbit will face issues with space debris in an already crowded orbit
- Concern for couple jailed in Tehran as British embassy closes
- CDC pauses dozens of types of lab testing during evaluation and in wake of downsizing
- Spanish woman, 25, dies by legal euthanasia in case that drew national spotlight
- Common ADHD medication prescribed in childhood may protect against risk of psychosis
- Consumer experts: German petrol hikes rule won't bring down prices
- Kissing is an ‘evolutionary conundrum.’ Scientists just mapped its unexpected origins
- Find the Standards of Viable Refereeing: Settling Debates with Strategy
- 4 Sound blocking Earphones for Prevalent Sound and Solace
- Why is the Artemis 2 rocket launch different from all other rocket launches?
